Výsledky vyhledávání - "E. M. H. Schmitz"

Optimizing charge state distribution is a prerequisite for accurate protein biomarker quantification with LC-MS/MS, as illustrated by hepcidin measurement

Autor: Niels M. Leijten, L.G. Milroy, Volkher Scharnhorst, E. M. H. Schmitz, Daan van de Kerkhof, Luc Brunsveld, Joost L. J. van Dongen, Maarten A. C. Broeren

Publikováno v: Clinical Chemistry and Laboratory Medicine, 56(9), 1490-1497. Walter de Gruyter GmbH

Background: Targeted quantification of protein biomarkers with liquid chromatography-tandem mass spectrometry (LC-MS/MS) has great potential, but is still in its infancy. Therefore, we elucidated the influence of charge state distribution and matrix

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad1dd291c1246ad2ce579df5520a2fef
http://www.scopus.com/inward/record.url?scp=85047882628&partnerID=8YFLogxK

Zobrazit plný text záznamu

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study

Autor: M. E. C. van de Poll, Luc Brunsveld, Luc J J Derijks, E. M. H. Schmitz, Maarten A. C. Broeren, Volkher Scharnhorst, P. J. Boekema, Jan Willem A Straathof, D. C. van Renswouw

Publikováno v: Alimentary Pharmacology and Therapeutics, 47(3), 356-363. Wiley-Blackwell

SummaryBackground Infliximab biosimilars have become available for treatment of inflammatory bowel disease (IBD). However, data showing long-term safety and effectiveness of biosimilars in IBD patients are limited. Aim To study prospectively the swit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::496a1c5eea49ece308996ba530f1cde0
https://doi.org/10.1111/apt.14453

Zobrazit plný text záznamu

A value proposition for trough level-based anti-TNFα drug dosing

Autor: E. M. H. Schmitz, Maarten A. C. Broeren, D. van de Kerkhof, Luc J J Derijks, Volkher Scharnhorst

Publikováno v: Clinica Chimica Acta, 489, 89-95. Elsevier

Treatment of inflammatory bowel diseases and rheumatic disorders with anti-tumor necrosis factor alpha (TNFα) drugs is expensive, while a significant proportion of patients does not show adequate clinical response. Therapeutic drug monitoring (TDM)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9702b528150951b8e16ffad0947a3ec1
https://pubmed.ncbi.nlm.nih.gov/30521801

Zobrazit plný text záznamu

Therapeutic drug monitoring of infliximab : performance evaluation of three commercial ELISA kits

Autor: Maarten A. C. Broeren, PH Kuijper, Joost L. J. van Dongen, Dörte Hamann, Luc Brunsveld, E. M. H. Schmitz, Daan van de Kerkhof, Volkher Scharnhorst

Publikováno v: Clinical Chemistry and Laboratory Medicine, 54(7). Walter de Gruyter GmbH

Background: Therapeutic drug monitoring (TDM) of infliximab (IFX, Remicade®) can aid to optimize therapy efficacy. Many assays are available for this purpose. However, a reference standard is lacking. Therefore, we evaluated the analytical performan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1af0c7d43ec9ef733a38f595f85af09
https://research.tue.nl/nl/publications/40c8db4c-3fff-4818-8ddd-df03f8de9828